Centralizing biological samples for patients with blood cancers
Official title: Pilot Study to Assess the Feasibility of Centralizing Biological Samples at Onset and Relapse of Patients Referred to CROP Centers for Molecular Characterization of Oncohematologic Pathology
Run by Meyer Children's Hospital IRCCS · NCT06304194 · Data updated 2026-11-12
This study is trying to collect and analyze blood samples from young patients with blood cancers to help improve treatments and research for these conditions.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 0 Years to 30 Years |
| Sex | All |
| Enrollment | 340 (estimated) |
| Sponsor | Meyer Children's Hospital IRCCS Academic / other |
| Locations | 3 sites (Florence and 2 other locations) |
| Status | Recruiting |
| Started | July 5, 2023 |
| Main results expected | July 5, 2027 |
| Study ends | July 5, 2028 |
| Registry record updated | March 12, 2024 |
| Trial ID | NCT06304194 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients aged 0 to 30 years with a diagnostic suspicion or recurrence of oncologic, hematologic, or onco-immunologic diseases.
✕Probably not a fit
Patients who may not benefit from this study include those with insufficient biological material for analysis or those with HIV, HCV, or HBV seropositivity.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on the molecular characterization of onco-hematological and hematological diseases in patients suspected of having these conditions. It aims to centralize biological samples at the IRCCS AOU Meyer Oncohematology Laboratories to facilitate the analysis of mutations in tumor tissue. By collecting and analyzing clinical data, the study seeks to establish a translational database that could support future pediatric oncohematology research and targeted therapies. The initiative is particularly aimed at enhancing the treatment of patients aged 0 to 30 years.
Why it matters
Potential benefit: If successful, this study could lead to improved targeted therapies for pediatric patients with oncohematological diseases.
How similar studies have gone: While this approach is innovative in its focus on pediatric oncohematology, similar studies have shown promise in the centralization and molecular analysis of cancer samples.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnostic suspicion of oncologic, hematologic or onco-immunologic disease * Suspected recurrence of oncological, onco-hematological, hematological or onco -immunological disease * Availability of biological material * Signature of informed consent * Age between 0 and 30 years Exclusion Criteria: * Failure to sign the consent * Insufficiency of biological material for analysis * Patients with HIV, HCV and HBV seropositivity (HBSAg) due to biohazard and bias related to patients' immunological status that could influence gene expression and tumor behavior.
Where it's running
-
Meyer Children's Hospital IRCCS
Florence, Italy Recruiting -
Azienda Ospedaliero-Universitaria Pisana
Pisa, Italy Recruiting -
Azienda Ospedaliero-Universitaria Senese
Siena, Italy Recruiting
Study contacts
- Principal investigator: Marinella Veltroni — Meyer Children's Hospital IRCCS
- Study coordinator: Marinella Veltroni
- Email: marinella.veltroni@meyer.it
- Phone: 0555662606
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Romiplostim to help platelets grow after donor stem cell transplant
This phase II trial tests whether weekly romiplostim helps patients over 18 who receive a haploidentical or fully matched unrelated donor stem cell transplant to engraft platelets faster than best supportive care.
-
How often older adults with cancer get a big drop in blood pressure right after anesthesia induction
We will test how often and why older adults with cancer have a large drop in blood pressure within the first 20 minutes after being put under general anesthesia.
-
IL-5 CAR-T therapy for refractory or relapsed eosinophilic leukemia
We will test whether IL-5 CAR-T cells can help adults with CD125-positive refractory or relapsed eosinophilic leukemia.
-
Exploring immune defects in young patients with blood disorders
This study is trying to find out how immune system problems affect young people under 25 with blood disorders like autoimmune issues and bone marrow failure.
-
HLA mismatched stem cell transplantation for hematologic diseases
This study is testing if using stem cells from donors who aren't a perfect match can help people with blood cancers get the treatment they need when they can't find a suitable donor.
-
Go Wish Game to support advance care planning for adults with cancer or blood cancers
This project tries the Go Wish Game to help adults with refractory leukemia, lymphoma, multiple myeloma, or advanced solid tumors and their caregivers have end-of-life conversations and complete advance care planning.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.